UWA's innovations are having a global impact
UWA's innovations have been commercialised or are under development with partners around the world.Find out more
- A simple blood test that was developed at UWA can predict and diagnose whether a patient will develop diabetic kidney disease up to 4 years before clinical symptoms appear. In clinical studies, PromarkerD predicted 86% of previously disease-free patients who went on to develop diabetic kidney disease within four years.
Diagnosing diabetic kidney disease early allows the patient to take steps to protect their kidneys from further damage. PromarkerD has been commercialised by Proteomics International.
- OncoRes Medical Pty Ltd
- OncoRes Medical Pty Ltd is developing a handheld imaging technology to provide intraoperative information to surgeons to assist with the identification of tumour and healthy tissue - based on a novel combination of optical coherence tomography imaging and elastography to provide a rapid evaluation of tissue microarchitecture at a scale and resolution comparable to histology.
The initial focus is on the development of an imaging probe that will enable breast cancer surgeons to identify residual cancer within the cavity following the excision of the tumour, providing a solution to address the high re-excision rates for breast cancer patients. Read more
- Gas Capture Technologies
- Research at the Australian Centre for LNG Futures lead to the development of a novel adsorbent that facilitates separation of methane from nitrogen – one of the most challenging separation problems in the gas & LNG industry – normally solved by (capital and energy intensive) cryogenic separation. Gas Capture Technologies has been formed to commercialise this technology, with applications for unconventional gas sources and low grade methane recovery.
- Developed within the School of Molecular Sciences, CrystalExplorer is a versatile and powerful suite of graphical and computational tools for the analysis of molecular crystal structures. It can be used to investigate many areas of solid-state chemistry and crystal engineering including intermolecular interactions and has been licensed to global pharmaceutical companies.
- MMEx ? Medical Message Exchange
- Designed by clinicians for clinicians, MMEx began at the University of Western Australia as a vision to facilitate secure communication between health professionals. Today MMEx is a comprehensive electronic health record provided by ISA Healthcare Solutions who remain committed to a research and clinician-led approach to software.
- ALT WellCAD
- Developed by the Centre for Exploration Targeting (CET), the automated structure detection and analysis software for downhole ?Televiewer? images improve the speed and quality of processing of downhole images in the minerals and petroleum industries.
- Developed at UWA, iCeutica's proprietary SoluMatrix Fine Particle Technology? creates new drugs with improved efficacy, better side effect profiles and more convenient dosing. iCeutica was acquired by Iroku Pharmaceuticals in 2011 and has gone on to apply the technology to develop and launch a range of painkillers, with other reformulated drugs in development.
- Poseidon Scientific Instruments/Raytheon - Sapphire Crystal Oscillators
- The technology was first licensed to newly formed PSI in 1995 leading to a 20+ year partnership between UWA & PSI. The real world impact of the technology was recognised with an ATSE Clunies Ross award in 2014; The oscillators were in high demand e.g. for precision radar systems, eventually leading to the acquisition of PSI (and UWA?s patent portfolio) by Raytheon in 2012. (pp 42-43)
- Echo360/Lectopia Lecture Capture system
- UWA developed the Lectopia lecture capture system from 1999 for internal use, then licenced it to 17 universities, and finally sold the software (and business) to Anystream Apreso in 2007 ? the product is now known as Echo360 (and is widely used at UWA).